Cellebrite DI (NASDAQ:CLBT) Reaches New 1-Year Low - Here's Why

Key Points

• Cellebrite DI shares hit a new 52-week low of $11.30 on Friday and last traded around $11.66 on volume of roughly 947,531 shares (prior close $12.41).
• Analysts hold a consensus rating of Moderate Buy with a $22.50 price target (four Buys, one Sell); some firms have recently adjusted views and targets, including Needham cutting its target to $18.
• The company reported quarterly EPS of $0.14 (in line) and revenue of $128.82M, up 28.8% year-over-year; Cellebrite has a $2.8 billion market cap, a PE of 36.29, and roughly 45.9% institutional ownership after several large purchases.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) shares reached a new 52-week low during trading on Friday . The stock traded as low as $11.30 and last traded at $11.6640, with a volume of 947531 shares trading hands. The stock had previously closed at $12.41.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Wall Street Zen upgraded Cellebrite DI from a "sell" rating to a "hold" rating in a report on Sunday, March 15th. Needham & Company LLC lowered their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, February 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cellebrite DI in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cellebrite DI presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.50.

Cellebrite DI Stock Performance

The firm has a market cap of $2.80 billion, a PE ratio of 36.29, a PEG ratio of 2.06 and a beta of 1.28. The stock has a fifty day moving average price of $14.08 and a 200-day moving average price of $16.52.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business had revenue of $128.82 million during the quarter, compared to analysts' expectations of $126.07 million. During the same quarter in the previous year, the business earned $0.10 EPS. The company's revenue for the quarter was up 28.8% on a year-over-year basis. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Institutional investors have recently modified their holdings of the company. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI in the 3rd quarter worth approximately $55,999,000. Granahan Investment Management LLC boosted its holdings in Cellebrite DI by 1,108.5% in the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company's stock worth $48,721,000 after acquiring an additional 2,411,726 shares during the period. Capital International Investors purchased a new position in Cellebrite DI in the 4th quarter worth approximately $41,073,000. Invesco Ltd. boosted its holdings in Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company's stock worth $103,030,000 after acquiring an additional 2,054,644 shares during the period. Finally, Pertento Partners LLP boosted its holdings in Cellebrite DI by 57.8% in the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company's stock worth $86,131,000 after acquiring an additional 1,702,574 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.